Compare AAME & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | SCLX |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 27.9M |
| IPO Year | 1995 | 2020 |
| Metric | AAME | SCLX |
|---|---|---|
| Price | $1.34 | $2.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 865.2K | 41.0K |
| Earning Date | 10-16-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ 221.74 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $210,440,000.00 | $30,253,000.00 |
| Revenue This Year | N/A | $118.16 |
| Revenue Next Year | N/A | $186.31 |
| P/E Ratio | $5.71 | ★ N/A |
| Revenue Growth | ★ 11.80 | N/A |
| 52 Week Low | $1.03 | $2.45 |
| 52 Week High | $3.24 | $27.00 |
| Indicator | AAME | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 16.71 |
| Support Level | $1.26 | N/A |
| Resistance Level | $1.66 | $7.77 |
| Average True Range (ATR) | 0.12 | 0.25 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 46.61 | 5.06 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.